Dendritic cells in the skin - Potential use for melanoma treatment

Pigment Cell and Melanoma Research

Volumn 22, Issue 1, 2009, Pages 30-41

  El Marsafy, Sanaa ^a   Bagot, Martine ^a   Bensussan, Armand ^a   Mauviel, Alain ^a  

^a INSERM   (France)

Author keywords

Cytotoxic T lymphocytes; Dendritic cells (DC); Immune tolerance; Immunotherapy; Melanoma; Regulatory T cells (Treg); Tumor antigens

Indexed keywords

DENDRITIC CELL VACCINE;

ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INTERNALIZATION; LANGERHANS CELL; MELANOMA; NONHUMAN; PATTERN RECOGNITION; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SKIN CARCINOGENESIS; SKIN CARCINOMA; STEADY STATE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; HUMANS; MELANOMA; SKIN; SKIN NEOPLASMS;

EID: 58449132546     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2008.00532.x     Document Type: Review

References (153)

1. Al-Alwan, M.M., Rowden, G., Lee, T.D. West, K.A. (2001). Fascin is involved in the antigen presentation activity of mature dendritic cells. J. Immunol. 166, 338 345.
2. Al-Batran, S.E., Rafiyan, M.R., Atmaca, A., Neumann, A., Karbach, J., Bender, A., Weidmann, E., Altmannsberger, H.M., Knuth, A. Jager, E. (2005). Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res. 65, 3937 3941.
3. Allen, P.J. Coit, D.G. (2002). The surgical management of metastatic melanoma. Ann. Surg. Oncol. 9, 762 770.
4. Angel, C.E., Lala, A., Chen, C.J., Edgar, S.G., Ostrovsky, L.L. Dunbar, P.R. (2007). CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. Int. Immunol. 19, 1271 1279.
5. Aspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton, E.C., Su, D., Marches, F., Banchereau, J. Palucka, A.K. (2007). Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J. Exp. Med. 204, 1037 1047.
6. Banchereau, J. Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature 392, 245 252.
7. Banchereau, J., Palucka, A.K., Dhodapkar, M. et al. (2001). Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451 6458.
8. Barois, N., de Saint-Vis, B., Lebecque, S., Geuze, H.J. Kleijmeer, M.J. (2002). MHC class II compartments in human dendritic cells undergo profound structural changes upon activation. Traffic 3, 894 905.
9. Belli, F., Testori, A., Rivoltini, L. et al. (2002). Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20, 4169 4180.
10. Bendriss-Vermare, N., Barthelemy, C., Durand, I., Bruand, C., Dezutter-Dambuyant, C., Moulian, N., Berrih-Aknin, S., Caux, C., Trinchieri, G. Briere, F. (2001). Human thymus contains IFN-alpha-producing CD11c(-), myeloid CD11c(+), and mature interdigitating dendritic cells. J. Clin. Invest. 107, 835 844.
11. Berard, F., Blanco, P., Davoust, J., Neidhart-Berard, E.M., Nouri-Shirazi, M., Taquet, N., Rimoldi, D., Cerottini, J.C., Banchereau, J. Palucka, A.K. (2000). Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192, 1535 1544.
12. Blander, J.M. Medzhitov, R. (2006). Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440, 808 812.
13. Blesson, S., Thiery, J., Gaudin, C., Stancou, R., Kolb, J.P., Moreau, J.L., Theze, J., Mami-Chouaib, F. Chouaib, S. (2002). Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO. Int. Immunol. 14, 1169 1178.
14. Blom, B., Ho, S., Antonenko, S. Liu, Y.J. (2000). Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J. Exp. Med. 192, 1785 1796.
15. Briere, F., Bendriss-Vermare, N., Delale, T. et al. (2002). Origin and filiation of human plasmacytoid dendritic cells. Hum. Immunol. 63, 1081 1093.
16. Bronte, V. Zanovello, P. (2005). Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5, 641 654.
17. Buisson, S. Triebel, F. (2005). LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors. Immunology 114, 369 374.
18. Bursch, L.S., Wang, L., Igyarto, B., Kissenpfennig, A., Malissen, B., Kaplan, D.H. Hogquist, K.A. (2007). Identification of a novel population of Langerin+ dendritic cells. J. Exp. Med. 204, 3147 3156.
19. Candido, K.A., Shimizu, K., McLaughlin, J.C., Kunkel, R., Fuller, J.A., Redman, B.G., Thomas, E.K., Nickoloff, B.J. Mule, J.J. (2001). Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res. 61, 228 236.
20. Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten, C., Durand, I. Banchereau, J. (1994). Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180, 1263 1272.
21. Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Durand, I., Cella, M., Lanzavecchia, A. Banchereau, J. (1997). CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 90, 1458 1470.
22. Caux, C., Ait-Yahia, S., Chemin, K., de Bouteiller, O., Dieu-Nosjean, M.C., Homey, B., Massacrier, C., Vanbervliet, B., Zlotnik, A. Vicari, A. (2000). Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin. Immunopathol. 22, 345 369.
23. Chang, A.E., Redman, B.G., Whitfield, J.R., Nickoloff, B.J., Braun, T.M., Lee, P.P., Geiger, J.D. Mule, J.J. (2002). A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8, 1021 1032.
24. Chapman, P.B. (2007). Melanoma vaccines. Semin. Oncol. 34, 516 523.
25. Chen, Q., Daniel, V., Maher, D.W. Hersey, P. (1994). Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer 56, 755 760.
26. Chen, W., Antonenko, S., Sederstrom, J.M., Liang, X., Chan, A.S., Kanzler, H., Blom, B., Blazar, B.R. Liu, Y.J. (2004). Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors. Blood 103, 2547 2553.
27. Chen, M., Wang, Y.H., Wang, Y., Huang, L., Sandoval, H., Liu, Y.J. Wang, J. (2006). Dendritic cell apoptosis in the maintenance of immune tolerance. Science 311, 1160 1164.
28. Chen, X., Baumel, M., Mannel, D.N., Howard, O.M. Oppenheim, J.J. (2007). Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J. Immunol. 179, 154 161.
29. Cormier, J.N., Xing, Y., Ding, M., Lee, J.E., Mansfield, P.F., Gershenwald, J.E., Ross, M.I. Du, X.L. (2005). Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J. Clin. Oncol. 23, 6054 6062.
30. Cranmer, L.D. Hersh, E. (2007). The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 25, 613 631.
31. Diebold, S.S. (2008). Determination of T-cell fate by dendritic cells. Immunol. Cell Biol. 86, 389 397.
32. Dong, H., Strome, S.E., Salomao, D.R. et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793 800.
33. Dudziak, D., Kamphorst, A.O., Heidkamp, G.F. et al. (2007). Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107 111.
34. Enk, A.H., Jonuleit, H., Saloga, J. Knop, J. (1997). Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer 73, 309 316.
35. Esche, C., Shurin, G.V., Kirkwood, J.M., Wang, G.Q., Rabinowich, H., Pirtskhalaishvili, G. Shurin, M.R. (2001). Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin. Cancer Res. 7, 974s 979s.
36. Estourgie, S. H., Nieweg, O. E. Kroon, B. B. (2004). High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br. J. Surg. 91, 1370 1371.
37. Fischer, K., Hoffmann, P., Voelkl, S. et al. (2007). Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812 3819.
38. Forster, R., Davalos-Misslitz, A.C. Rot, A. (2008). CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol. 8, 362 371.
39. Fuchs, E.J. Matzinger, P. (1996). Is cancer dangerous to the immune system? Semin. Immunol. 8, 271 280.
40. Gandhi, R., Anderson, D.E. Weiner, H.L. (2007). Cutting Edge: Immature human dendritic cells express latency-associated peptide and inhibit T cell activation in a TGF-beta-dependent manner. J. Immunol. 178, 4017 4021.
41. Gatti, E. Pierre, P. (2003). Understanding the cell biology of antigen presentation: the dendritic cell contribution. Curr. Opin. Cell Biol. 15, 468 473.
42. Gerlini, G., Tun-Kyi, A., Dudli, C., Burg, G., Pimpinelli, N. Nestle, F.O. (2004). Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am. J. Pathol. 165, 1853 1863.
43. Gershenwald, J.E., Thompson, W., Mansfield, P.F., Lee, J.E., Colome, M.I., Tseng, C.H., Lee, J.J., Balch, C.M., Reintgen, D.S. Ross, M.I. (1999). Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J. Clin. Oncol. 17, 976 983.
44. Gold, L.I. (1999). The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit. Rev. Oncog. 10, 303 360.
45. Gordon, L.K., Ribas, A., Nusinowitz, S., Butterfield, L.H., Glaspy, J.A., Economou, J.S. Straatsma, B.R. (2004). Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Control. Clin. Trials 25, 400 407.
46. Gottfried, E., Kunz-Schughart, L.A., Ebner, S., Mueller-Klieser, W., Hoves, S., Andreesen, R., Mackensen, A. Kreutz, M. (2006). Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107, 2013 2021.
47. Grouard, G., Rissoan, M.C., Filgueira, L., Durand, I., Banchereau, J. Liu, Y.J. (1997). The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. 185, 1101 1111.
48. Grover, A., Kim, G.J., Lizee, G., Tschoi, M., Wang, G., Wunderlich, J.R., Rosenberg, S.A., Hwang, S.T. Hwu, P. (2006). Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin. Cancer Res. 12, 5801 5808.
49. Hayday, A. Tigelaar, R. (2003). Immunoregulation in the tissues by gammadelta T cells. Nat. Rev. Immunol. 3, 233 242.
50. Henrickson, S.E., Mempel, T.R., Mazo, I.B. et al. (2008). In vivo imaging of T cell priming. Sci. Signal 1, pt2.
51. Hersey, P., Bindon, C., Czerniecki, M., Spurling, A., Wass, J. McCarthy, W.H. (1983). Inhibition of interleukin 2 production by factors released from tumor cells. J. Immunol. 131, 2837 2842.
52. Hiltbold, E.M., Vlad, A.M., Ciborowski, P., Watkins, S.C. Finn, O.J. (2000). The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. 165, 3730 3741.
53. Houot, R., Perrot, I., Garcia, E., Durand, I. Lebecque, S. (2006). Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J. Immunol. 176, 5293 5298.
54. Hsiao, Y.W., Liao, K.W., Hung, S.W. Chu, R.M. (2004). Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J. Immunol. 172, 1508 1514.
55. Hsueh, E.C., Gupta, R.K., Yee, R., Leopoldo, Z.C., Qi, K. Morton, D.L. (2000). Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann. Surg. Oncol. 7, 232 238.
56. Hunder, N.N., Wallen, H., Cao, J., Hendricks, D.W., Reilly, J.Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J.A. Yee, C. (2008). Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698 2703.
57. Hussein, M.R. (2005). Dendritic cells and melanoma tumorigenesis: an insight. Cancer Biol. Ther. 4, 501 505.
58. Hwu, P., Du, M.X., Lapointe, R., Do, M., Taylor, M.W. Young, H.A. (2000). Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164, 3596 3599.
59. Ito, M., Minamiya, Y., Kawai, H., Saito, S., Saito, H., Nakagawa, T., Imai, K., Hirokawa, M. Ogawa, J. (2006). Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J. Immunol. 176, 5637 5643.
60. Jack, A., Boyes, C., Aydin, N., Alam, K. Wallack, M. (2006). The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surg. Oncol. 15, 13 24.
61. Jaksits, S., Kriehuber, E., Charbonnier, A.S., Rappersberger, K., Stingl, G. Maurer, D. (1999). CD34+ cell-derived CD14+ precursor cells develop into Langerhans cells in a TGF-beta 1-dependent manner. J. Immunol. 163, 4869 4877.
62. Javelaud, D., Mohammad, K.S., McKenna, C.R. et al. (2007). Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res. 67, 2317 2324.
63. Javelaud, D., Alexaki, V.I. Mauviel, A. (2008). Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res. 21, 123 132.
64. Jiang, Q., Wei, H. Tian, Z. (2008). IFN-producing Killer Dendritic Cells Contribute to the Inhibitory Effect of Poly I:C on the Progression of Murine Melanoma. J. Immunother. 31, 555 562.
65. Kemp, T.J., Elzey, B.D. Griffith, T.S. (2003). Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J. Immunol. 171, 212 218.
66. Khayat, D., Rixe, O., Martin, G. et al. (2003). Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 97, 1941 1946.
67. Kissenpfennig, A., Henri, S., Dubois, B. et al. (2005). Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22, 643 654.
68. Kleijmeer, M., Ramm, G., Schuurhuis, D. et al. (2001). Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. J. Cell Biol. 155, 53 63.
69. Kobayashi, M., Suzuki, K., Yashi, M., Yuzawa, M., Takayashiki, N. Morita, T. (2007). Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res. 27, 1137 1141.
70. Kouskoff, V. Nemazee, D. (2001). Role of receptor editing and revision in shaping the B and T lymphocyte repertoire. Life Sci. 69, 1105 1113.
71. Kryczek, I., Wei, S., Zou, L., Zhu, G., Mottram, P., Xu, H., Chen, L. Zou, W. (2006a). Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J. Immunol. 177, 40 44.
72. Kryczek, I., Zou, L., Rodriguez, P. et al. (2006b). B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871 881.
73. Kukreja, A., Hutchinson, A., Dhodapkar, K., Mazumder, A., Vesole, D., Angitapalli, R., Jagannath, S. Dhodapkar, M.V. (2006). Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J. Exp. Med. 203, 1859 1865.
74. Kurts, C., Heath, W.R., Kosaka, H., Miller, J.F. Carbone, F.R. (1998). The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J. Exp. Med. 188, 415 420.
75. Kyte, J.A., Mu, L., Aamdal, S. et al. (2006). Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 13, 905 918.
76. Ladanyi, A., Kiss, J., Somlai, B., Gilde, K., Fejos, Z., Mohos, A., Gaudi, I. Timar, J. (2007). Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother. 56, 1459 1469.
77. Le Borgne, M., Etchart, N., Goubier, A. et al. (2006). Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 24, 191 201.
78. Lechler, R., Chai, J.G., Marelli-Berg, F. Lombardi, G. (2001). T-cell anergy and peripheral T-cell tolerance. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 625 637.
79. Lee, K.H., Wang, E., Nielsen, M.B., Wunderlich, J., Migueles, S., Connors, M., Steinberg, S.M., Rosenberg, S.A. Marincola, F.M. (1999). Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163, 6292 6300.
80. Lee, J.C., Lee, K.M., Kim, D.W. Heo, D.S. (2004). Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172, 7335 7340.
81. Lindquist, R.L., Shakhar, G., Dudziak, D., Wardemann, H., Eisenreich, T., Dustin, M.L. Nussenzweig, M.C. (2004). Visualizing dendritic cell networks in vivo. Nat. Immunol. 5, 1243 1250.
82. Maeurer, M.J., Gollin, S.M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W.J. Lotze, M.T. (1996). Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 98, 1633 1641.
83. Mahabeleshwar, G.H. Byzova, T.V. (2007). Angiogenesis in melanoma. Semin. Oncol. 34, 555 565.
84. Mahdian, R., Kokhaei, P., Najar, H.M., Derkow, K., Choudhury, A. Mellstedt, H. (2006). Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells. Med. Oncol. 23, 273 282.
85. Mahnke, K., Johnson, T.S., Ring, S. Enk, A.H. (2007a). Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J. Dermatol. Sci. 46, 159 167.
86. Mahnke, K., Ring, S., Johnson, T.S., Schallenberg, S., Schonfeld, K., Storn, V., Bedke, T. Enk, A.H. (2007b). Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur. J. Immunol. 37, 2117 2126.
87. Maraskovsky, E., Brasel, K., Teepe, M., Roux, E.R., Lyman, S.D., Shortman, K. McKenna, H.J. (1996). Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953 1962.
88. Matasic, R., Dietz, A.B. Vuk-Pavlovic, S. (2001). Maturation of human dendritic cells as sulfasalazine target. Croat. Med J. 42, 440 445.
89. Mellor, A.L. Munn, D.H. (2004). IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762 774.
90. van Mierlo, G.J., Boonman, Z.F., Dumortier, H.M., den Boer, A.T., Fransen, M.F., Nouta, J., van der Voort, E.I., Offringa, R., Toes, R.E. Melief, C.J. (2004). Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J. Immunol. 173, 6753 6759.
91. Mignot, G., Ullrich, E., Bonmort, M. et al. (2008). The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J. Immunol. 180, 6477 6483.
92. Min, S.Y., Park, K.S., Cho, M.L. et al. (2006). Antigen-induced, tolerogenic CD11c+,CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum. 54, 887 898.
93. Molavi, O., Ma, Z., Hamdy, S., Lai, R., Lavasanifar, A. Samuel, J. (2008). Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunol. Cell Biol. 86, 506 514.
94. Moller, P., Moller, H., Sun, Y., Dorbic, T., Henz, B.M., Wittig, B. Schadendorf, D. (2000). Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells. Cancer Gene Ther. 7, 976 984.
95. Munn, D.H., Sharma, M.D., Lee, J.R. et al. (2002). Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867 1870.
96. Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. Schadendorf, D. (1998). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328 332.
97. Oliveira, J.B. Fleisher, T. (2004). Autoimmune lymphoproliferative syndrome. Curr. Opin. Allergy Clin. Immunol. 4, 497 503.
98. Osada, T., Chong, G., Tansik, R. et al. (2008). The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57, 1115 1124.
99. Pierre, P. Mellman, I. (1998). Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 93, 1135 1145.
100. Pluddemann, A., Neyen, C. Gordon, S. (2007). Macrophage scavenger receptors and host-derived ligands. Methods 43, 207 217.
101. Poulin, L.F., Henri, S., de Bovis, B., Devilard, E., Kissenpfennig, A. Malissen, B. (2007). The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells. J. Exp. Med. 204, 3119 3131.
102. Powell, J.D. (2006). The induction and maintenance of T cell anergy. Clin. Immunol. 120, 239 246.
103. Powell, D.J. Jr., Felipe-Silva, A., Merino, M.J. et al. (2007). Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J. Immunol. 179, 4919 4928.
104. Probst, H.C., McCoy, K., Okazaki, T., Honjo, T. van den Broek, M. (2005). Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6, 280 286.
105. Pulendran, B., Banchereau, J., Burkeholder, S. et al. (2000). Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165, 566 572.
106. Rasku, M.A., Clem, A.L., Telang, S. et al. (2008). Transient T cell depletion causes regression of melanoma metastases. J. Transl. Med. 6, 12.
107. Reis e Sousa, C. (2004). Activation of dendritic cells: translating innate into adaptive immunity. Curr. Opin. Immunol. 16, 21 25.
108. Ringborg, U., Andersson, R., Eldh, J., Glaumann, B., Hafstrom, L., Jacobsson, S., Jonsson, P.E., Johansson, H., Krysander, L. Lagerlof, B. (1996). Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 77, 1809 1814.
109. Rodeck, U., Nishiyama, T. Mauviel, A. (1999). Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells. Cancer Res. 59, 547 550.
110. Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P. Amigorena, S. (1999). Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1, 362 368.
111. Romagnani, S. (2006). Immunological tolerance and autoimmunity. Intern. Emerg. Med. 1, 187 196.
112. Ross, R., Jonuleit, H., Bros, M., Ross, X.L., Yamashiro, S., Matsumura, F., Enk, A.H., Knop, J. Reske-Kunz, A.B. (2000). Expression of the actin-bundling protein fascin in cultured human dendritic cells correlates with dendritic morphology and cell differentiation. J. Invest. Dermatol. 115, 658 663.
113. Rutella, S., Danese, S. Leone, G. (2006). Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108, 1435 1440.
114. Saleh, F., Renno, W., Klepacek, I., Ibrahim, G., Asfar, S., Dashti, H., Romero, P., Dashti, A. Behbehani, A. (2005). Melanoma immunotherapy: past, present, and future. Curr. Pharm. Des. 11, 3461 3473.
115. Schneeberger, A., Luhrs, P., Kutil, R., Steinlein, P., Schild, H., Schmidt, W. Stingl, G. (2003). Granulocyte-macrophage colony-stimulating factor-based melanoma cell vaccines immunize syngeneic and allogeneic recipients via host dendritic cells. J. Immunol. 171, 5180 5187.
116. Schreiber, S., Kampgen, E., Wagner, E. et al. (1999). Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum. Gene Ther. 10, 983 993.
117. Schwartz, R.H. (2003). T cell anergy. Annu. Rev. Immunol. 21, 305 334.
118. Schwartz, R.H., Mueller, D.L., Jenkins, M.K. Quill, H. 1989). T-cell clonal anergy. Cold Spring Harb. Symp. Quant. Biol. 54 Pt 2, 605 610.
119. Shevach, E.M., DiPaolo, R.A., Andersson, J., Zhao, D.M., Stephens, G.L. Thornton, A.M. (2006). The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212, 60 73.
120. Shukuwa, T., Katayama, I. Koji, T. (2002). Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas. Mod. Pathol. 15, 387 396.
121. Siegal, F.P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P.A., Shah, K., Ho, S., Antonenko, S. Liu, Y.J. (1999). The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835 1837.
122. Simonetti, O., Goteri, G., Lucarini, G., Rubini, C., Stramazzotti, D., Lo Muzio, L., Biagini, G. Offidani, A. (2007). In melanoma changes of immature and mature dendritic cell expression correlate with tumor thickness:an immunohistochemical study. Int. J. Immunopathol. Pharmacol. 20, 325 333.
123. Singh, N.J. Schwartz, R.H. (2006). Primer: mechanisms of immunologic tolerance. Nat. Clin. Pract. Rheumatol. 2, 44 52.
124. Sporri, R. Reis e Sousa, C. (2005). Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 6, 163 170.
125. Stranges, P.B., Watson, J., Cooper, C.J. et al. (2007). Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity 26, 629 641.
126. Suh, W.K., Gajewska, B.U., Okada, H. et al. (2003). The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4, 899 906.
127. Suss, G. Shortman, K. (1996). A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 183, 1789 1796.
128. Tas, F., Duranyildiz, D., Oguz, H., Camlica, H., Yasasever, V. Topuz, E. (2008). Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med. Oncol. 25, 431 436.
129. Teicher, B.A. (2001). Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev. 20, 133 143.
130. Thomas, J.M. Clark, M.A. (2004). Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur. J. Surg. Oncol. 30, 686 691.
131. Thurner, B., Haendle, I., Roder, C. et al. (1999). Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669 1678.
132. Trefzer, U., Herberth, G., Wohlan, K., Milling, A., Thiemann, M., Sherev, T., Sparbier, K., Sterry, W. Walden, P. (2004). Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int. J. Cancer 110, 730 740.
133. Trombetta, E.S. Mellman, I. (2005). Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23, 975 1028.
134. Trombetta, E.S., Ebersold, M., Garrett, W., Pypaert, M. Mellman, I. (2003). Activation of lysosomal function during dendritic cell maturation. Science 299, 1400 1403.
135. Tuettenberg, A., Schmitt, E., Knop, J. Jonuleit, H. (2007). Dendritic cell-based immunotherapy of malignant melanoma: success and limitations. J. Dtsch. Dermatol. Ges. 5, 190 196.
136. Ueno, H., Klechevsky, E., Morita, R. et al. (2007). Dendritic cell subsets in health and disease. Immunol. Rev. 219, 118 142.
137. Valencia, X., Stephens, G., Goldbach-Mansky, R., Wilson, M., Shevach, E.M. Lipsky, P.E. (2006). TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108, 253 261.
138. Veronesi, U. Cascinelli, N. (1991). Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch. Surg. 126, 438 441.
139. Villadangos, J.A., Schnorrer, P. Wilson, N.S. (2005). Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol. Rev. 207, 191 205.
140. Vlad, A.M., Kettel, J.C., Alajez, N.M., Carlos, C.A. Finn, O.J. (2004). MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82, 249 293.
141. de Vries, I.J., Lesterhuis, W.J., Scharenborg, N.M. et al. (2003). Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9, 5091 5100.
142. Wallet, M.A., Sen, P., Flores, R.R. et al. (2008). MerTK is required for apoptotic cell-induced T cell tolerance. J. Exp. Med. 205, 219 232.
143. Weaver, C.T., Harrington, L.E., Mangan, P.R., Gavrieli, M. Murphy, K.M. (2006). Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24, 677 688.
144. Wei, S., Kryczek, I. Zou, W. (2006). Regulatory T-cell compartmentalization and trafficking. Blood 108, 426 431.
145. Weishaupt, C., Munoz, K.N., Buzney, E., Kupper, T.S. Fuhlbrigge, R.C. (2007). T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin. Cancer Res. 13, 2549 2556.
146. Williams, J.M., Colman, R., Brookes, C.J., Savage, C.O. Harper, L. (2005). Anti-endothelial cell antibodies from lupus patients bind to apoptotic endothelial cells promoting macrophage phagocytosis but do not induce apoptosis. Rheumatology (Oxford) 44, 879 884.
147. Wong, S.L. Coit, D.G. (2004). Role of surgery in patients with stage IV melanoma. Curr. Opin. Oncol. 16, 155 160.
148. Workman, C.J. Vignali, D.A. (2005). Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J. Immunol. 174, 688 695.
149. Yamazaki, S., Iyoda, T., Tarbell, K., Olson, K., Velinzon, K., Inaba, K. Steinman, R.M. (2003). Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198, 235 247.
150. Yates, J., Rovis, F., Mitchell, P., Afzali, B., Tsang, J.Y., Garin, M., Lechler, R.I., Lombardi, G. Garden, O.A. (2007). The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int. Immunol. 19, 785 799.
151. Zang, X. Allison, J.P. (2007). The B7 family and cancer therapy: costimulation and coinhibition. Clin. Cancer Res. 13, 5271 5279.
152. Zea, A.H., Rodriguez, P.C., Atkins, M.B. et al. (2005). Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65, 3044 3048.
153. Zhang, N., Hartig, H., Dzhagalov, I., Draper, D. He, Y.W. (2005). The role of apoptosis in the development and function of T lymphocytes. Cell Res. 15, 749 769.